OBJECTIVES: According to JNC 7 guidelines, most hypertensive patients require multiple drugs—as individual agents or fixed-dose combinations (FDCs)—to achieve blood pressure goals. They suggest that FDCs may be simplest, most convenient, and most cost-effective. However, usage patterns for FDCs are not fully known. Our objective was to explore prescription treatment patterns for monotherapy and combination therapy for US adults with diagnosed hypertension. METHODS: Data were obtained from the 2007 US National Health and Wellness Survey (NHWS) quarters 1-3. The NHWS is an annual, nationally representative, Internet-based survey of adults (≥ 18 years). Respondents were asked about their hypertension and its treatment. Drugs reported were compared for monotherapy versus combinations (single agents and/or FDCs) and grouped by class: angiotensin II receptor blockers (ARBs), α- or β-blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, and diuretics including hydrochlorothiazide. RESULTS: Respondents numbered 19,874. Of 16,495 (83%) who reported using prescription therapy, 215 (1%) responded ambiguously, whereas 7705 (47%) received single-agent monotherapy: an ACE inhibitor (2828 [37%] of 7705), a β-blocker (1796 [23%]), or something else. The remaining 8575 (52% of 16,495) patients received combination therapies: two single agents with no FDC (3516 [41%] of 8575), three or more single agents with no FDC (2285 [27%]), an FDC alone (1517 [18%]), an FDC plus one agent (744 [9%]), an FDC plus two single agents (432 [5%]), or other (81 [1%]). Common FDC-only therapies were an ARB + hydrochlorothiazide (713 [47%] of 1517 patients), and an ACE inhibitor + CCB (384 [25%]). CONCLUSIONS: More than half of the hypertensive respondents to the NHWS received at least two antihypertensive agents, with the majority receiving multiple individual products instead of an FDC product. Understanding the factors contributing to this use profile, such as cost, availability, convenience, and compliance, requires further exploration.